vs
Digimarc CORP（DMRC）与MAXCYTE, INC.（MXCT）财务数据对比。点击上方公司名可切换其他公司
Digimarc CORP的季度营收约是MAXCYTE, INC.的1.9倍（$8.9M vs $4.8M），Digimarc CORP净利率更高（-47.2% vs -200.5%，领先153.2%），Digimarc CORP同比增速更快（2.9% vs -20.9%），Digimarc CORP自由现金流更多（$895.0K vs $-2.9M），过去两年Digimarc CORP的营收复合增速更高（-5.3% vs -7.4%）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
DMRC vs MXCT — 直观对比
营收规模更大
DMRC
是对方的1.9倍
$4.8M
营收增速更快
DMRC
高出23.8%
-20.9%
净利率更高
DMRC
高出153.2%
-200.5%
自由现金流更多
DMRC
多$3.8M
$-2.9M
两年增速更快
DMRC
近两年复合增速
-7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $4.8M |
| 净利润 | $-4.2M | $-9.6M |
| 毛利率 | 63.5% | — |
| 营业利润率 | -48.2% | -234.5% |
| 净利率 | -47.2% | -200.5% |
| 营收同比 | 2.9% | -20.9% |
| 净利润同比 | 51.4% | 9.4% |
| 每股收益（稀释后） | $-0.18 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCMXCT
| Q4 25 | $8.9M | $4.8M | ||
| Q3 25 | $7.6M | $4.6M | ||
| Q2 25 | $8.0M | $5.8M | ||
| Q1 25 | $9.4M | $5.7M | ||
| Q4 24 | $8.7M | $6.1M | ||
| Q3 24 | $9.4M | $5.6M | ||
| Q2 24 | $10.4M | $5.0M | ||
| Q1 24 | $9.9M | $5.6M |
净利润DMRCMXCT
| Q4 25 | $-4.2M | $-9.6M | ||
| Q3 25 | $-8.2M | $-12.4M | ||
| Q2 25 | $-8.2M | $-12.4M | ||
| Q1 25 | $-11.7M | $-10.3M | ||
| Q4 24 | $-8.6M | $-10.6M | ||
| Q3 24 | $-10.8M | $-11.6M | ||
| Q2 24 | $-9.3M | $-9.4M | ||
| Q1 24 | $-10.3M | $-9.5M |
毛利率DMRCMXCT
| Q4 25 | 63.5% | — | ||
| Q3 25 | 58.3% | — | ||
| Q2 25 | 58.8% | — | ||
| Q1 25 | 65.0% | — | ||
| Q4 24 | 60.8% | — | ||
| Q3 24 | 62.4% | — | ||
| Q2 24 | 66.1% | — | ||
| Q1 24 | 62.5% | — |
营业利润率DMRCMXCT
| Q4 25 | -48.2% | -234.5% | ||
| Q3 25 | -109.7% | -307.4% | ||
| Q2 25 | -105.2% | -244.3% | ||
| Q1 25 | -128.9% | -214.1% | ||
| Q4 24 | -105.1% | -213.1% | ||
| Q3 24 | -120.4% | -250.4% | ||
| Q2 24 | -96.2% | -241.0% | ||
| Q1 24 | -109.2% | -219.8% |
净利率DMRCMXCT
| Q4 25 | -47.2% | -200.5% | ||
| Q3 25 | -106.9% | -269.7% | ||
| Q2 25 | -102.6% | -212.2% | ||
| Q1 25 | -125.2% | -178.7% | ||
| Q4 24 | -99.9% | -175.0% | ||
| Q3 24 | -113.9% | -205.9% | ||
| Q2 24 | -89.3% | -188.8% | ||
| Q1 24 | -104.0% | -170.6% |
每股收益（稀释后）DMRCMXCT
| Q4 25 | $-0.18 | — | ||
| Q3 25 | $-0.38 | $-0.12 | ||
| Q2 25 | $-0.38 | $-0.12 | ||
| Q1 25 | $-0.55 | — | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.50 | $-0.11 | ||
| Q2 24 | $-0.43 | $-0.09 | ||
| Q1 24 | $-0.50 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $103.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $40.2M | $171.5M |
| 总资产 | $53.0M | $202.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DMRCMXCT
| Q4 25 | $12.9M | $103.0M | ||
| Q3 25 | $12.6M | $105.7M | ||
| Q2 25 | $16.1M | $126.6M | ||
| Q1 25 | $21.6M | $138.3M | ||
| Q4 24 | $28.7M | $154.5M | ||
| Q3 24 | $33.7M | $153.8M | ||
| Q2 24 | $41.5M | $157.3M | ||
| Q1 24 | $48.9M | $157.5M |
股东权益DMRCMXCT
| Q4 25 | $40.2M | $171.5M | ||
| Q3 25 | $41.4M | $180.3M | ||
| Q2 25 | $46.5M | $190.7M | ||
| Q1 25 | $50.0M | $199.4M | ||
| Q4 24 | $61.4M | $206.3M | ||
| Q3 24 | $70.2M | $213.3M | ||
| Q2 24 | $77.2M | $221.3M | ||
| Q1 24 | $84.5M | $226.4M |
总资产DMRCMXCT
| Q4 25 | $53.0M | $202.5M | ||
| Q3 25 | $55.4M | $213.5M | ||
| Q2 25 | $60.7M | $219.8M | ||
| Q1 25 | $66.5M | $230.0M | ||
| Q4 24 | $75.8M | $239.5M | ||
| Q3 24 | $85.0M | $248.6M | ||
| Q2 24 | $93.4M | $251.5M | ||
| Q1 24 | $99.7M | $257.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-2.7M |
| 自由现金流经营现金流 - 资本支出 | $895.0K | $-2.9M |
| 自由现金流率自由现金流/营收 | 10.0% | -61.0% |
| 资本支出强度资本支出/营收 | 1.1% | 4.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-36.2M |
8季度趋势，按日历期对齐
经营现金流DMRCMXCT
| Q4 25 | $991.0K | $-2.7M | ||
| Q3 25 | $-2.6M | $-7.5M | ||
| Q2 25 | $-4.7M | $-9.9M | ||
| Q1 25 | $-5.5M | $-14.4M | ||
| Q4 24 | $-4.2M | $-7.8M | ||
| Q3 24 | $-7.1M | $-4.4M | ||
| Q2 24 | $-6.8M | $-4.8M | ||
| Q1 24 | $-8.4M | $-10.6M |
自由现金流DMRCMXCT
| Q4 25 | $895.0K | $-2.9M | ||
| Q3 25 | $-2.8M | $-7.8M | ||
| Q2 25 | $-4.9M | $-10.4M | ||
| Q1 25 | $-5.5M | $-15.1M | ||
| Q4 24 | $-4.2M | $-8.0M | ||
| Q3 24 | $-7.2M | $-4.8M | ||
| Q2 24 | $-6.9M | $-5.1M | ||
| Q1 24 | $-8.5M | $-11.4M |
自由现金流率DMRCMXCT
| Q4 25 | 10.0% | -61.0% | ||
| Q3 25 | -36.9% | -168.5% | ||
| Q2 25 | -61.0% | -179.2% | ||
| Q1 25 | -59.1% | -262.3% | ||
| Q4 24 | -49.1% | -131.6% | ||
| Q3 24 | -75.7% | -85.5% | ||
| Q2 24 | -66.1% | -103.3% | ||
| Q1 24 | -85.8% | -203.6% |
资本支出强度DMRCMXCT
| Q4 25 | 1.1% | 4.8% | ||
| Q3 25 | 2.9% | 6.5% | ||
| Q2 25 | 2.5% | 10.0% | ||
| Q1 25 | 0.6% | 11.4% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.7% | 7.2% | ||
| Q2 24 | 0.3% | 5.9% | ||
| Q1 24 | 1.1% | 14.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
